Edwards Lifesciences Corporation (NYSE:EW) is one of the best medical technology stocks to invest in. On February 11, Stifel reiterated its Buy rating on Edwards Lifesciences and kept its price target at $110. Stifel made the move right after Edwards Lifesciences shared its Q4 2025 earnings on February 10. The results showed that quarterly sales went up by 11.6% to $1.57 billion and beat Stifel and consensus estimates of $1.54 billion and $1.55 billion, respectively.
In the earnings report, Edwards Lifesciences’ transcatheter aortic valve replacement (TAVR) sales, which account for about 74% of the company’s 2025 revenue, grew 10.6% year over year during the quarter. Stifel noted that this segment was the main driver of the company’s blowout performance.
Edwards Lifesciences reported quarterly EPS of $0.58, which fell short of Stifel and consensus expectations of $0.62. This happened because the company spent more than expected on sales, general, and administrative costs to support its business and growth plans.
Management kept its 2026 financial outlook and said spending will be more controlled. They pointed to strong TAVR growth drivers like good clinical results, new European guidelines, a competitor leaving the market, and rising use of the Sapien 3 Ultra Resilia valve with solid pricing.
Edwards Lifesciences Corporation (NYSE:EW) develops and manufactures medical technology focused on structural heart disease and critical care monitoring. Its primary products include transcatheter heart valves, surgical heart valves and hemodynamic monitoring systems for intensive care settings.
While we acknowledge the potential of EW as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 12 Best Foreign Stocks to Buy Right Now and 11 Best AI Penny Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.